cypriumtx.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot /
BingBot /
BaiduSpider /
YandexBot /
Meta Tags
Title Cyprium Therapeutics Inc. | Developing new therapeutics for rare pediatric
Description Cyprium Therapeutics, home ABOUT Management Team Board of Directors PIPELINE About Menkes Disease CUTX-101 (Copper Histidinate) AAV-ATP7A Gene Therapy Development Pathway Publi
Keywords N/A
Server Information
WebSite cypriumtx faviconcypriumtx.com
Host IP 155.130.138.21
Location United States
Related Websites
Site Rank
More to Explore
cypriumtx.com Valuation
US$2,408,899
Last updated: 2023-05-15 18:15:36

cypriumtx.com has Semrush global rank of 4,393,836. cypriumtx.com has an estimated worth of US$ 2,408,899, based on its estimated Ads revenue. cypriumtx.com receives approximately 277,950 unique visitors each day. Its web server is located in United States, with IP address 155.130.138.21. According to SiteAdvisor, cypriumtx.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$2,408,899
Daily Ads Revenue US$2,224
Monthly Ads Revenue US$66,708
Yearly Ads Revenue US$800,496
Daily Unique Visitors 18,530
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
cypriumtx.com. A 3598 IP: 155.130.138.21
cypriumtx.com. NS 7200 NS Record: ns21.worldnic.com.
cypriumtx.com. NS 7200 NS Record: ns22.worldnic.com.
cypriumtx.com. MX 3600 MX Record: 10 cypriumtx-com.mail.protection.outlook.com.
cypriumtx.com. TXT 3600 TXT Record: v=spf1 include:spf.protection.outlook.com -all
HtmlToTextCheckTime:2023-05-15 18:15:36
home ABOUT Management Team Board of Directors PIPELINE About Menkes Disease CUTX-101 (Copper Histidinate) AAV-ATP7A Gene Therapy Development Pathway Publications Expanded Access Policy Business Development Investors & Media Press Releases Corporate Presentation Resources CONTACT US Cyprium Therapeutics, Inc. Cyprium, a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. Expanded Access Policy CUTX-101 is under investigation for the treatment of Menkes disease and related copper metabolism disorders. It has not yet been established as safe and effective for any such treatment. Cyprium Therapeutics believes that CUTX-101 should be available and studied in patients as part of an Intermediate-Size Patient Population Expanded Access Protocol to obtain further data on the safety and efficacy of CUTX-101 that may be used to support approval of the product and subsequent wider accessibility to
HTTP Headers
HTTP/1.1 301 Moved Permanently
Server: nginx
Date: Fri, 07 Jan 2022 09:31:50 GMT
Content-Type: text/html; charset=UTF-8
Connection: keep-alive
X-Powered-By: PHP/7.2.34
X-Redirect-By: WordPress
Location: https://www.cypriumtx.com/
Vary: User-Agent
X-Powered-By: PleskLin

HTTP/2 200 
server: nginx
date: Fri, 07 Jan 2022 09:31:51 GMT
content-type: text/html; charset=UTF-8
vary: Accept-Encoding
x-powered-by: PHP/7.2.34
link: ; rel="https://api.w.org/", ; rel="alternate"; type="application/json", ; rel=shortlink
vary: User-Agent
x-powered-by: PleskLin
cypriumtx.com Whois Information
Domain Name: CYPRIUMTX.COM
Registry Domain ID: 2091608626_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2021-11-21T09:31:20Z
Creation Date: 2017-01-20T15:07:12Z
Registry Expiry Date: 2023-01-20T15:07:12Z
Registrar: Network Solutions, LLC
Registrar IANA ID: 2
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS21.WORLDNIC.COM
Name Server: NS22.WORLDNIC.COM
DNSSEC: unsigned
>>> Last update of whois database: 2022-01-07T23:44:37Z <<<